Ascendia

  MARKET NEWS

Kymera Therapeutics Announces First Patient Dosed in BROADEN Phase 1b Atopic Dermatitis Clinical Trial of First-in-Class Oral STAT6 Degrader
March Biosciences Announces First Patient Dosed in Phase 2 Clinical Trial of First-in-Class CD5 CAR-T Cell Therapy for T-Cell Lymphoma
Ocean Biomedical Expands Into Energy & Digital Asset Sectors to Accelerate Growth & Shareholder Value
Phlow Corp. Expands Analytical Capabilities & Embraces AI-Driven System, Ushering in a New Era of Modern Medicine Manufacturing in America
Kindeva Bolsters Executive Team With Chief Quality Officer
Vaccinex to Report Promising New Clinical Data Revealing Pepinemab’s Unique Mechanism to Enhance Immunotherapy
Ligand Subsidiary Pelthos Therapeutics to Combine With Channel Therapeutics
eschbach Introduces SAMI: The Next Evolution in AI-Empowered Process Manufacturing
Lonza Joins Centre for Continuous Manufacturing & Advanced Crystallisation to Enhance Service Offering
Cullinan Therapeutics Receives Approval From EMA to Initiate Phase 1 Trial of a Bispecific CD19 T Cell Engager Administered Subcutaneously in Patients With RA

  EXPERT CONTENT & RESOURCES

 

How to Choose the Right CDMO for Your Pharmaceutical Project

How to Choose the Right CDMO for Your Pharmaceutical Project

This guide outlines the fundamental considerations to ensure your CDMO selection aligns with your project goals.

Understanding the Foundation of LNP Formulation Success

Understanding the Foundation of LNP Formulation Success

Download our eBook and discover everything you need to know about lipids for developing LNP therapies, including:….

Lyophilization Development: Quality by Design Approach

Lyophilization Development: Quality by Design Approach

Lyophilization, or freeze-drying, addresses stability challenges associated with complex APIs, biologics, microbiomes, gene therapies, viral vectors, liposomes, and nanoparticles……

  FEATURED EDITORIAL

  COMPANY PROFILE

Upperton is a UK-based CDMO providing integrated contract development and manufacturing services. Specialising in oral, nasal, pulmonary and sterile dosage forms, Upperton offers a comprehensive range of services designed to support the progression of a molecule from early feasibility through to formulation development, clinical trial manufacture and commercial manufacture. With over 25 years of experience, Upperton excels in rapid product introductions. Click here for more.

Click image to see Serán Bioscience’s latest video

Click image to see Captisol’s latest video

  WHITEPAPERS & WEBINARS

WEBINAR ON DEMAND: Precision at Scale: Enabling Novel Therapeutics With Nanoparticle Manufacturing

WEBINAR ON DEMAND: Precision at Scale: Enabling Novel Therapeutics With Nanoparticle Manufacturing

Watch this on-demand webinar to learn about the key steps and considerations in bringing novel nanoparticle-based therapeutics from early R&D to commercial stages. Drawing from our 20 years of experience in the CDMO space, we cover critical topics unique to nanomaterials…..

WEBINAR: Introducing Key Concepts in Tableting Research: Unleashing Essential Concepts and Strategies for Enhanced Formulation Development

WEBINAR: Introducing Key Concepts in Tableting Research: Unleashing Essential Concepts and Strategies for Enhanced Formulation Development

Tableting can present a series of challenges, particularly when dealing with formulations that have poor flowability, low compressibility, or high cohesivity. These issues can lead to manufacturing inefficiencies….

  WHITEPAPERS & WEBINARS

WHITEPAPER - 3D SCREEN Printing: Enabling a New Generation of Complex Formulations

WHITEPAPER - 3D SCREEN Printing: Enabling a New Generation of Complex Formulations

The pharmaceutical industry has been acquainted with the promise of 3D printing for some time now, with many large pharma companies exploring the possibilities of the technology. However, 3D-printed pharmaceuticals have been largely relegated to niche markets and prototyping due …

 WHITEPAPER - Formulating Custom Viscosity Blends With POLYOX™ Polyethylene Oxide 

 WHITEPAPER - Formulating Custom Viscosity Blends With POLYOX™ Polyethylene Oxide 


Excipient variability plays a critical role in pharmaceutical product design. A risk-based, scientific approach to Quality by Design (QbD) is essential to ensure consistent drug performance.

Our latest whitepaper delves into the impact of POLYOX™ PEO (Polyethylene Oxide) on drug …

ARTICLE - A New Framework for Identifying Nitrosamine Risks & Efficiently Derisking Products

ARTICLE - A New Framework for Identifying Nitrosamine Risks & Efficiently Derisking Products

A clear standard for identifying APIs susceptible to Nitrosamine Drug Substance-Related Impurities (NDSRI) formation has been elusive—until now. Adare’s team of nitrosamine experts have developed a straightforward framework that simplifies the identification of at-risk APIs. Discover how this innovative approach …

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

April 30 – Controlled Release
May 7 – Nasal Drug Delivery